The bacteria was blocking the dengue virus inside the mosquito itself
In the long human struggle against mosquito-borne disease, a Brazilian scientist named Luciano Moreira has been recognized by Time magazine among the world's hundred most influential people for 2026 — not for a dramatic intervention, but for a patient, biological one. Working through Fiocruz and building on Australian research, Moreira helped develop a method of infecting Aedes aegypti mosquitoes with Wolbachia bacteria, which blocks dengue transmission from within the insect itself. The recognition honors not one mind but many, and points to a quiet revolution now unfolding across fifteen countries — a reminder that some of humanity's most consequential breakthroughs arrive not with fanfare, but through years of careful, collaborative observation.
- Dengue remains one of the world's most widespread and debilitating mosquito-borne illnesses, placing millions at risk each year with no simple cure in sight.
- The Wolbachia method upends conventional mosquito control by turning the insect itself into a carrier of protection rather than a target for elimination.
- After more than four years of painstaking microinjection work, the technique became self-sustaining — female mosquitoes pass the bacteria to their offspring naturally, removing the need for repeated intervention.
- In Rio de Janeiro and Niterói, over 90% of wild Aedes aegypti mosquitoes still carry Wolbachia more than a decade after initial releases, signaling that the biological shift has held.
- Now active in 15 countries and 16 Brazilian municipalities, the program is testing whether a solution born in one context can protect people across vastly different environments.
- Time's recognition follows Nature's 2025 honor, together framing Moreira's work as a defining scientific contribution of the era — one he insists belongs to the entire team behind it.
Luciano Moreira was in a studio when he learned that Time magazine had named him one of the hundred most influential people in the world for 2026. The Brazilian scientist, based at Fiocruz, was selected in the Innovators category for his role in developing and scaling a method to fight dengue using mosquitoes infected with a bacterium called Wolbachia. He received the news with surprise, and later said the recognition truly belonged to the team that had spent years building something now operating across fifteen countries and sixteen Brazilian municipalities.
The technique traces its origins to Australia, where Moreira worked as a postdoctoral researcher alongside Scott O'Neill. The two were studying Wolbachia's effects on fruit flies when they noticed the bacterium shortened the insects' lifespan. The initial plan was to introduce it into Aedes aegypti mosquitoes to reduce how long they lived — fewer aging mosquitoes meant less time for dengue to develop and spread. But testing revealed something far more significant: Wolbachia didn't merely shorten the mosquito's life. It blocked the dengue virus from taking hold in the insect's body entirely.
Translating that discovery into a deployable tool required more than four years of work developing a microinjection technique precise enough to introduce purified Wolbachia into mosquito eggs. Once done, the bacteria sustained itself — female mosquitoes passed it to their offspring naturally, meaning researchers needed only to breed and release the infected insects. In Rio de Janeiro and Niterói, where releases began between 2014 and 2015, over ninety percent of wild Aedes aegypti still carried Wolbachia more than a decade later.
The Time honor followed Nature magazine's recognition of Moreira as one of ten people who shaped science in 2025. In both cases, he pointed beyond himself — to the accumulated dedication of many researchers whose small discoveries had built into something capable of changing how the world confronts one of its most persistent diseases.
Luciano Moreira was sitting in a studio when the news arrived: Time magazine had named him one of the hundred most influential people in the world for 2026. The Brazilian scientist, who works at Fiocruz, had been selected in the Innovators category for his work developing and expanding a method to fight dengue using mosquitoes infected with a bacterium called Wolbachia. He was surprised by the honor, he said later. But the recognition, he believed, belonged to the team that had spent years building something that now operates across fifteen countries and sixteen Brazilian municipalities.
The story of how this technique came to exist begins in Australia, where Moreira worked as a postdoctoral researcher alongside Scott O'Neill, a pioneer in the field. The two scientists were studying what happened when Wolbachia infected fruit flies. They noticed something: the bacterium shortened the insects' lifespan. O'Neill's initial idea was straightforward—introduce the bacterium into Aedes aegypti mosquitoes, the species that spreads dengue, and reduce how long they lived. Fewer old mosquitoes meant less time for the virus to develop inside them and spread to humans. But during testing, the researchers discovered something far more powerful than they had anticipated. The Wolbachia didn't just shorten the mosquito's life. It blocked the dengue virus directly, preventing infection from taking hold in the insect's body at all.
Turning that discovery into a working tool took patience. The team spent more than four years developing a microinjection technique precise enough to insert the purified Wolbachia—originally derived from fruit flies—into the eggs of Aedes aegypti mosquitoes. Once that initial step was complete, the bacteria did the rest of the work on its own. Female mosquitoes naturally passed the Wolbachia to their offspring through their eggs. This meant that after the initial injection, researchers didn't need to repeat the process. They could simply breed the infected mosquitoes in large numbers and release them into the wild, where they would continue spreading the protective bacterium through the population.
In areas of Rio de Janeiro and Niterói where the program began releasing these mosquitoes between 2014 and 2015, more than ninety percent of the wild Aedes aegypti population still carried Wolbachia more than a decade later. The persistence suggested the technique was working as intended—the bacteria had taken hold and was sustaining itself. The program had expanded far beyond Brazil's borders, reaching countries across multiple continents, each one testing whether a solution developed in one place could protect people in another.
Moreira's recognition by Time came a year after Nature magazine had already named him one of ten people who shaped science in 2025. When asked about these honors, he emphasized that they reflected something larger than individual achievement. Years of dedication from many researchers, he said, had produced the evidence and rigor that gave the program its credibility both internationally and at home. The work was collaborative, built on small discoveries that accumulated into something that could change how the world approached a disease that had plagued millions. What had begun as a question about how a bacterium affected insect lifespan had become a tool deployed across continents, a quiet revolution in how humans could fight back against one of the most persistent mosquito-borne illnesses on Earth.
Citas Notables
The bacterium was blocking the dengue virus inside the mosquito. That was the major discovery that really changed the entire concept, and from there the international program began, now operating in 15 countries and 16 Brazilian municipalities.— Luciano Moreira
I was very surprised. What brought me the most happiness is seeing that this was teamwork. Many people have been working for years, dedicating themselves to this program, doing cutting-edge science and bringing very important evidence to give the program the robustness it has.— Luciano Moreira
La Conversación del Hearth Otra perspectiva de la historia
How did a scientist working with fruit flies in Australia end up creating a dengue solution that now operates in fifteen countries?
It started with observation. Scott O'Neill noticed that Wolbachia shortened the lifespan of fruit flies. The leap was asking: what if we put this bacterium into the mosquito that spreads dengue? But the real breakthrough came when they realized the bacterium didn't just kill the mosquito faster—it blocked the virus itself.
That must have changed everything about how they approached the problem.
Completely. Instead of trying to reduce mosquito populations through shorter lifespans, they had a tool that made the mosquitoes themselves unable to carry the virus. It reframed the entire strategy.
The microinjection process took four years. Why so long?
You're inserting a bacterium into a mosquito egg at a scale where precision matters enormously. One mistake and the whole approach fails. Four years was the time required to get it right.
Once they got it right, though, the bacteria spread on its own through the population.
Exactly. Female mosquitoes pass it to their offspring naturally. After that initial injection phase, you don't need to keep intervening. The biology does the work for you.
Over ninety percent of mosquitoes in Rio and Niterói still carry it years later. That's remarkable persistence.
It suggests the system is stable, that the bacteria has integrated into the wild population in a way that sustains itself. That's what makes it different from other control methods that require constant reapplication.
When Moreira talks about this being a team effort, what does he mean?
He means that recognition for a breakthrough like this obscures all the years of work by many people—the technicians, the field researchers, the epidemiologists tracking outcomes. The innovation is real, but it's collective.